▲ +119.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $30.75, with a high forecast of $38.00 and a low forecast of $25.00. The average price target represents a 119.64% upside from the last price of $14.00.
The current consensus among 5 polled investment analysts is to buy stock in Chinook Therapeutics.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.